Close Menu

NEW YORK – Investment bank Evercore ISI on Tuesday downgraded Qiagen's stock to an In Line rating from a previous Outperform rating and assigned a per-share price target of $42.

In a note to investors, Evercore ISI analyst Ross Muken and others said that although Qiagen appears that it will hit most of its long-term 2020 financial targets issued in 2016, recently issued long-term guidance of constant exchange rate growth of 8 percent to 9 percent by 2023 appears to be less of a sure thing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.